{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000686","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.466225+00:00","generated_at":"2026-06-15T09:42:04.193471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus Q1 net income $50.8M ($1.87 EPS) vs loss year ago; NDA filed for COVID vaccine ARCT-154 in Japan","bullets":["Revenue $80.3M (up from $5.2M YoY) driven by CSL Seqirus milestones; net income $50.8M vs loss of $51.2M.","NDA for ARCT-154 (COVID-19 vaccine) submitted in Japan by Meiji Seika Pharma; potential approval later 2023.","Cash $330.1M; long-term debt eliminated; expects $90M AR collection in Q2; runway extended into early 2026.","ARCT-032 Phase 1 enrollment complete; expansion to CF patients planned Q3 2023. ARCT-810 Phase 2 interim data on track for later 2023.","Received $23.6M advance from CSL Seqirus for manufacturing and supply of ARCT-154 in April."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000686","json":"https://secwatch.observer/filing/0001193805-23-000686.json","markdown":"https://secwatch.observer/filing/0001193805-23-000686.md","text":"https://secwatch.observer/filing/0001193805-23-000686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/0001193805-23-000686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/e618600_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:42:04.193471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d7cdc995966535a4f28df2a50b6866a8ba1337f","claim":"Arcturus Therapeutics Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $80.3 million.","evidence_excerpt":"Total revenue for the three months ended March 31, 2023, was $80.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/0001193805-23-000686-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$80.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}